+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nephrology Drugs Market by Drug Class, Route of Administration and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 267 Pages
  • December 2021
  • Region: Global
  • Allied Market Research
  • ID: 5548437
The global nephrology drugs market was valued at $14,501.75 million in 2020, and is projected to reach $23,405.42 million by 2030, registering a CAGR of 5.0% from 2021 to 2030.



Nephrology deals with diagnosis and the treatment related to kidney disorders as well as involves the management of kidney functioning. It further consists of other renal replacement therapies such as dialysis and kidney transplantation. Diabetes, hypertension, electrolytes disturbances, and autoimmune diseases are treated. Along with this, other diseases include acute kidney injury, hematuria, chronic kidney disease, proteinuria, disorders of electrolytes or acid/base, and kidney stones.

The factors that drive the growth of the global nephrology drugs market include rise in awareness & incidence of kidney diseases, changes in lifestyle, and rise in cases of diabetes & hypertension. Disorders such as chronic kidney disease and acute kidney diseases can be treated by nephrology drugs, which notably contributes toward the market growth. In addition, rise in awareness pertaining to kidney diseases and increase in investment in research, development, and innovation supplement the market growth, globally.

The nephrology drugs market is segmented into drug class, route of administration, distribution channel, and region. By drug class, the market is classified into ACE inhibitors, calcium channel blocker, beta blockers, diuretics, and others. Depending on route of administration, it is categorized into oral, parenteral, and others. On the basis of distribution channel, it is segregated into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major factors driving the growth of the nephrology drugs market are alarming rise in cases of kidney failures, surge in prevalence of various chronic nephrology diseases, adoption of unhealthy lifestyle, and rise in geriatric population. In addition, increase in alcohol consumption, rise in the number of diagnostic tests for kidney diseases, surge in obese population, rise in R&D activities for launch of novel drugs and improvement in the existing drugs, and emerging technology in developing economies are positively impacting the growth of the nephrology drugs market.

However, the cost of treatment for kidney disorders is high, which is expected to create hindrances for the growth of the nephrology drugs market. Moreover, lack of awareness in general population and low alertness about suffering from kidney diseases, and there has been an inclination of generic drugs are causing hurdles in the nephrology drugs market.

Various initiatives have been taken by the government to encourage the regulatory affairs in getting approvals for novel drugs, and insurance policies which are creating lucrative opportunities in the nephrology drugs market.

Region wise, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the nephrology drugs market in 2020, and is expected to retain its dominance throughout the forecast period. This is primarily attributed to the awareness regarding the chronic kidney diseases in this region. Moreover, rise in investments by key players in this region contributes toward the market growth.

Business expansions is the key strategy adopted by market players. The report provides a comprehensive analysis of the key players that operate in the global nephrology drugs market. The key companies profiled in the report include AstraZeneca, AbbVie Inc., Akebia Therapeutics, Inc., Amgen Inc., F. Hoffmann-La Roche, FibroGen Inc., GlaxoSmithkline PLC., Johnson & Johnson Inc., Pfizer Inc., and Teva Pharmaceutical Industries Limited.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides in-depth analysis of the global nephrology drugs market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global nephrology drugs market growth.

KEY MARKET SEGMENTS


By Drug Class

  • ACE inhibitors
  • Calcium channel blockers
  • Beta Blockers
  • Diuretics
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

List of key players profiled in the report:

  • AstraZeneca
  • Pfizer Inc.
  • Amgen Inc.
  • FibroGen Inc.
  • GlaxoSmithkline plc.
  • AbbVie Inc.
  • Akebia Therapeutics, Inc.
  • Teva Pharmaceutical Industries,
  • Johnson & Johnson Inc.
  • F. Hoffmann-La Roche.
Frequently Asked Questions about the Global Nephrology Drugs Market

What is the estimated value of the Global Nephrology Drugs Market?

The Global Nephrology Drugs Market was estimated to be valued at $14501.75 million in 2020.

What is the growth rate of the Global Nephrology Drugs Market?

The growth rate of the Global Nephrology Drugs Market is 4.9%, with an estimated value of $23405.42 million by 2030.

What is the forecasted size of the Global Nephrology Drugs Market?

The Global Nephrology Drugs Market is estimated to be worth $23405.42 million by 2030.

Who are the key companies in the Global Nephrology Drugs Market?

Key companies in the Global Nephrology Drugs Market include AstraZeneca, AbbVie Inc., Akebia Therapeutics, Inc., Amgen Inc., F. Hoffmann, La Roche, FibroGen Inc., GlaxoSmithkline PLC. and Pfizer Inc..

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increasing incidence of chronic kidney diseases
3.5.1.2. Technological Advancements in developing countries
3.5.1.3. Rising Investment by Key Players
3.5.2. Restraint
3.5.2.1. High treatment cost and lack of awareness for Chronic Kidney Diseases
3.5.3. Opportunities
3.5.3.1. Initiatives by Governments for regulatory approvals
3.6. Covid-19 Impact analysis on Nephrology Drugs market
CHAPTER 4: NEPHROLOGY MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. ACE inhibitors
4.2.1. Market size and forecast, by region
4.2.2. Market analysis, by country
4.3. Calcium Channel Blocker
4.3.1. Market size and forecast, by region
4.3.2. Market analysis, by country
4.4. Beta Blockers
4.4.1. Market size and forecast, by region
4.4.2. Market analysis, by country
4.5. Diuretics
4.5.1. Market size and forecast, by region
4.5.2. Market analysis, by country
4.6. Others
4.6.1. Market size and forecast, by region
4.6.2. Market analysis, by country
CHAPTER 5: NEPHROLOGY MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Parenteral
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: NEPHROLOGY MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacy
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Retail Pharmacy
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Online Pharmacy
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: NEPHROLOGY DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. Nephrology drugs market, by drug class
7.2.2.1.2. U.S. Nephrology drugs market, by route of administration
7.2.2.1.3. U.S. Nephrology drugs market, by distribution channel
7.2.2.2. Canada
7.2.2.2.1. Canada Nephrology drugs market, by drug class
7.2.2.2.2. Canada Nephrology drugs market, by route of administration
7.2.2.2.3. Canada Nephrology drugs market, by distribution channel
7.2.2.3. Mexico
7.2.2.3.1. Mexico Nephrology drugs market, by drug class
7.2.2.3.2. Mexico Nephrology drugs market, by route of administration
7.2.2.3.3. Mexico Nephrology drugs market, by distribution channel
7.2.3. North America market size and forecast, by drug class
7.2.4. North America market size and forecast, by route of administration
7.2.5. North America market size and forecast, by distribution channel
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany Nephrology drugs market, by drug class
7.3.2.1.2. Germany Nephrology drugs market, by route of administration
7.3.2.1.3. Germany Nephrology drugs market, by distribution channel
7.3.2.2. France
7.3.2.2.1. France Nephrology drugs market, by drug class
7.3.2.2.2. France Nephrology drugs market, by route of administration
7.3.2.2.3. France Nephrology drugs market, by distribution channel
7.3.2.3. UK
7.3.2.3.1. UK Nephrology drugs market, by drug class
7.3.2.3.2. UK Nephrology drugs market, by route of administration
7.3.2.3.3. UK Nephrology drugs market, by distribution channel
7.3.2.4. Italy
7.3.2.4.1. Italy Nephrology drugs market, by drug class
7.3.2.4.2. Italy Nephrology drugs market, by route of administration
7.3.2.4.3. Italy Nephrology drugs market, by distribution channel
7.3.2.5. Spain
7.3.2.5.1. Spain Nephrology drugs market, by drug class
7.3.2.5.2. Spain Nephrology drugs market, by route of administration
7.3.2.5.3. Spain Nephrology drugs market, by distribution channel
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe Nephrology drugs market, by drug class
7.3.2.6.2. Rest of Europe Nephrology drugs market, by route of administration
7.3.2.6.3. Rest of Europe Nephrology drugs market, by distribution channel
7.3.3. Europe market size and forecast, by drug class
7.3.4. Europe market size and forecast, by route of administration
7.3.5. Europe market size and forecast, by distribution channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan Nephrology drugs market, by drug class
7.4.2.1.2. Japan Nephrology drugs market, by route of administration
7.4.2.1.3. Japan Nephrology drugs market, by distribution channel
7.4.2.2. China
7.4.2.2.1. China Nephrology drugs market, by drug class
7.4.2.2.2. China Nephrology drugs market, by route of administration
7.4.2.2.3. China Nephrology drugs market, by distribution channel
7.4.2.3. Australia
7.4.2.3.1. Australia Nephrology drugs market, by drug class
7.4.2.3.2. Australia Nephrology drugs market, by route of administration
7.4.2.3.3. Australia Nephrology drugs market, by distribution channel
7.4.2.4. India
7.4.2.4.1. India Nephrology drugs market, by drug class
7.4.2.4.2. India Nephrology drugs market, by route of administration
7.4.2.4.3. India Nephrology drugs market, by distribution channel
7.4.2.5. Rest of Asia-Pacific
7.4.2.5.1. Rest of Asia-Pacific Nephrology drugs market, by drug class
7.4.2.5.2. Rest of Asia-Pacific Nephrology drugs market, by route of administration
7.4.2.5.3. Rest of Asia-Pacific Nephrology drugs market, by distribution channel
7.4.3. Asia-Pacific market size and forecast, by drug class
7.4.4. Asia-Pacific market size and forecast, by route of administration
7.4.5. Asia-Pacific market size and forecast, by distribution channel
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil Nephrology drugs market, by drug class
7.5.2.1.2. Brazil Nephrology drugs market, by route of administration
7.5.2.1.3. Brazil Nephrology drugs market, by distribution channel
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia Nephrology drugs market, by drug class
7.5.2.2.2. Saudi Arabia Nephrology drugs market, by route of administration
7.5.2.2.3. Saudi Arabia Nephrology drugs market, by distribution channel
7.5.2.3. South Africa
7.5.2.3.1. South Africa Nephrology drugs market, by drug class
7.5.2.3.2. South Africa Nephrology drugs market, by route of administration
7.5.2.3.3. South Africa Nephrology drugs market, by distribution channel
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA Nephrology drugs market, by drug class
7.5.2.4.2. Rest of LAMEA Nephrology drugs market, by route of administration
7.5.2.4.3. Rest of LAMEA Nephrology drugs market, by distribution channel
7.5.3. LAMEA market size and forecast, by drug class
7.5.4. LAMEA market size and forecast, by route of administration
7.5.5. LAMEA market size and forecast, by distribution channel
CHAPTER 8: COMPANY PROFILES
8.1. AstraZeneca PLC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Pfizer, Inc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Amgen Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. FibroGen Inc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. GlaxoSmithKline PLC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. AbbVie Inc.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Akebia Therapeutics, Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. Teva Pharmaceutical Industries Limited.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. Johnson and Johnson
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. F. HOFFMANN-LA ROCHE LTD.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
List of Tables
TABLE 01. NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 02. NEPHROLOGY DRUGS MARKET FOR ACE INHIBITORS, BY REGION, 2020-2030 ($MILLION)
TABLE 03. NEPHROLOGY DRUGS MARKET FOR CALCIUM CHANNEL BLOCKER, BY REGION, 2020-2030 ($MILLION)
TABLE 04. NEPHROLOGY DRUGS MARKET FOR BETA BLOCKERS, BY REGION, 2020-2030 ($MILLION)
TABLE 05. NEPHROLOGY DRUGS MARKET FOR DIURETICS, BY REGION, 2020-2030 ($MILLION)
TABLE 06. NEPHROLOGY DRUGS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 07. NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 08. NEPHROLOGY DRUGS MARKET FOR ORAL, BY REGION, 2020-2030 ($MILLION)
TABLE 09. NEPHROLOGY DRUGS MARKET FOR PARENTERAL, BY REGION, 2020-2030 ($MILLION)
TABLE 10. NEPHROLOGY DRUGS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 11. NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 12. NEPHROLOGY DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2020-2030 ($MILLION)
TABLE 13. NEPHROLOGY DRUGS MARKET FOR RETAIL PHARMACY, BY REGION, 2020-2030 ($MILLION)
TABLE 14. NEPHROLOGY DRUGS MARKET FOR ONLINE PHARMACY, BY REGION, 2020-2030 ($MILLION)
TABLE 15. NEPHROLOGY DRUGS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 16. NORTH AMERICA NEPHROLOGY DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 17. U.S. NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 18. U.S. NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 19. U.S. NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 20. CANADA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 21. CANADA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 22. CANADA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 23. MEXICO NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 24. MEXICO NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 25. MEXICO NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 26. NORTH AMERICA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 27. NORTH AMERICA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 28. NORTH AMERICA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 29. EUROPE NEPHROLOGY DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 30. GERMANY NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 31. GERMANY NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 32. GERMANY NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 33. FRANCE NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 34. FRANCE NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 35. FRANCE NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 36. UK NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 37. UK NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 38. UK NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 39. ITALY NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 40. ITALY NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 41. ITALY NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 42. SPAIN NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 43. SPAIN NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 44. SPAIN NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 45. REST OF EUROPE NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 46. REST OF EUROPE NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 47. REST OF EUROPE NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 48. EUROPE NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 49. EUROPE NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 50. EUROPE NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 51. ASIA-PACIFIC NEPHROLOGY DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 52. JAPAN NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 53. JAPAN NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 54. JAPAN NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 55. CHINA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 56. CHINA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 57. CHINA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 58. AUSTRALIA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 59. AUSTRALIA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 60. AUSTRALIA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 61. INDIA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 62. INDIA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 63. INDIA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 64. REST OF ASIA-PACIFIC NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 65. REST OF ASIA-PACIFIC NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 66. REST OF ASIA-PACIFIC NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 67. ASIA-PACIFIC NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 68. ASIA-PACIFIC NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 69. ASIA-PACIFIC NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 70. LAMEA NEPHROLOGY DRUGS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 71. BRAZIL NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 72. BRAZIL NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 73. BRAZIL NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 74. SAUDI ARABIA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 75. SAUDI ARABIA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 76. SAUDI ARABIA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 77. SOUTH AFRICA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 78. SOUTH AFRICA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 79. SOUTH AFRICA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 80. REST OF LAMEA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 81. REST OF LAMEA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 82. REST OF LAMEA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 83. LAMEA NEPHROLOGY DRUGS MARKET, BY DRUG CLASS, 2020-2030 ($MILLION)
TABLE 84. LAMEA NEPHROLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
TABLE 85. LAMEA NEPHROLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 86. ASTRAZENECA PLC.: COMPANY SNAPSHOT
TABLE 87. ASTRAZENECA PLC.: OPERATING SEGMENTS
TABLE 88. ASTRAZENECA PLC.: PRODUCT PORTFOLIO
TABLE 89. ASTRAZENECA PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 90. PFIZER INC.: COMPANY SNAPSHOT
TABLE 91. PFIZER: OPERATING SEGMENTS
TABLE 92. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 93. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 94. AMGEN INC.: COMPANY SNAPSHOT
TABLE 95. AMGEN INC.: OPERATING SEGMENTS
TABLE 96. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 97. FIBROGEN, INC.: COMPANY SNAPSHOT
TABLE 98. FIBROGEN, INC.: OPERATING SEGMENTS
TABLE 99. FIBROGEN, INC.: PRODUCT PORTFOLIO
TABLE 100. FIBROGEN, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 101. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 102. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
TABLE 103. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 104. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 105. ABBVIE INC: COMPANY SNAPSHOT
TABLE 106. ABBVIE INC.: OPERATING SEGMENTS
TABLE 107. ABBVIE INC: PRODUCT PORTFOLIO
TABLE 108. AKEBIA THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 109. AKEBIA THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 110. AKEBIA THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 111. TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: COMPANY SNAPSHOT
TABLE 112. TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: OPERATING SEGMENTS
TABLE 113. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 114. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 115. J&J: COMPANY SNAPSHOT
TABLE 116. J&J: OPERATING BUSINESS SEGMENTS
TABLE 117. J&J: PRODUCT PORTFOLIO
TABLE 118. F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 119. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
TABLE 120. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. NEPHROLOGY DRUGS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS IN NEPHROLOGY DRUGS MARKET, 2020
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2019-2021*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021*
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
FIGURE 01. LOW-MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 02. HIGH BARGAINING POWER OF BUYERS
FIGURE 03. MODERATE THREAT OF SUBSTITUTES
FIGURE 04. MODERATE THREAT OF NEW ENTRANTS
FIGURE 05. HIGH INTENSITY OF COMPETITIVE RIVALRY
FIGURE 06. TOP PLAYER POSITIONING, 2020
FIGURE 07. COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR ACE INHIBITORS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 08. COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR CALCIUM CHANNEL BLOCKER, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 09. COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR BETA BLOCKERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 10. COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR DIURETICS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR ORAL, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR CALCIUM CHANNEL BLOCKER, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF NEPHROLOGY DRUGS MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18. ASTRAZENECA PLC.: NET SALES, 2018-2020 ($ MILLION)
FIGURE 19. ASTRAZENECA PLC.: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 20. ASTRAZENECA PLC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 21. PFIZER INC.: NET SALES, 2018-2020 ($ MILLION)
FIGURE 22. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 23. PFIZER INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 24. AMGEN INC.: NET SALES, 2018-2020 ($ MILLION)
FIGURE 25. AMGEN INC.: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 26. FIBROGEN, INC.NET SALES, 2018-2020 ($ MILLION)
FIGURE 27. FIBROGEN, INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 28. GLAXOSMITHKLINE PLC.: NET SALES, 2018-2020 ($ MILLION)
FIGURE 29. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 30. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 31. ABBVIE INC: NET SALES, 2018-2020 ($ MILLION)
FIGURE 32. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 33. ABBVIE INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 34. AKEBIA THERAPEUTICS, INC.: NET SALES, 2018-2020 ($ MILLION)
FIGURE 35. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES, 2018-2020 ($ MILLION)
FIGURE 36. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 37. J&J: NET SALES, 2018-2020 ($ MILLION)
FIGURE 38. J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39. J&J: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2018-2020 ($ MILLION)
FIGURE 41. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 42. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2020 (%)

Companies Mentioned

  • AstraZeneca
  • AbbVie Inc.
  • Akebia Therapeutics, Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche
  • FibroGen Inc.
  • GlaxoSmithkline PLC.
  • Johnson & Johnson Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...